Capricor Therapeutics (CAPR) News Today

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is under pressure as numerous law firms publicize a securities class-action lawsuit and a September 28, 2026 deadline for investors to seek appointment as lead plaintiff. The legal campaign follows concerns about the company’s disclosures surrounding its Phase 3 HOPE-3 trial and the FDA’s review of Capricor’s biologics license application.

• Neutral Sentiment: Investors who purchased Capricor securities between December 17, 2025, and July 26, 2026, may seek lead-plaintiff status by September 28. The announcements are largely investor solicitations and do not establish that Capricor violated securities laws. Faruqi & Faruqi Capricor investor notice
• Negative Sentiment: The lawsuit alleges Capricor told investors that HOPE-3 results were statistically significant while failing to disclose that the final statistical analysis plan was changed one day before unblinding and allegedly had not been agreed to by the FDA. These claims raise concerns about the reliability of the trial data and prior company disclosures. Levi & Korsinsky Capricor lawsuit notice
• Negative Sentiment: Multiple firms say FDA briefing documents exposed the alleged statistical-plan changes and intensified regulatory and disclosure scrutiny. The FDA has also extended its review of Capricor’s biologics license application, adding uncertainty to the timing and prospects for approval. Hagens Berman Capricor investor deadline notice
• Negative Sentiment: The continuing stream of class-action announcements increases headline, litigation, and potential financial risks for Capricor. The stock has already declined sharply from its 12-month high of $40.37 and remains below its 50-day and 200-day moving averages, reflecting weakened investor confidence.

Overall, the recent news is predominantly negative for CAPR: investors are weighing litigation exposure and questions about HOPE-3 data integrity against the company’s still-unresolved regulatory review. Capricor has not been found liable based on these notices, but the allegations could continue to amplify volatility.